CEO of UnitedHealthcare, Brian Thompson, shot dead in New York City
Pharmaceutical Technology
DECEMBER 4, 2024
US police have confirmed that Brian Thompson was fatally shot outside an investor conference by a masked assailant.
Wed.Dec 04, 2024
147 
Targeting Cancer Drug Resistance with Kairos Pharma’s CEO Dr. John Yu
XTalks
DECEMBER 4, 2024
In this episode, Ayesha spoke with John Yu, MD, CEO of Kairos Pharma , a company advancing therapies to overcome challenges in cancer drug resistance and immune suppression. Kairos is developing therapeutics that reverse cancer drug resistance in cancers such as prostate and lung cancer. The company’s lead candidate, ENV105, is an antibody targeting CD105, which is implicated in cancer cell resistance to various treatments.
Join 21,000+
Insiders
Sign Up for our Newsletter
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Henrik Watz Featured in Free Educational Presentation Available for HCPs on COPD with Type 2 Inflammation
Velocity Clinical Research
DECEMBER 4, 2024
Congratulations to Henrik Watz, MD , on his exceptional presentation at the 2024 European Respiratory Society (ERS) ADVENT COPD Symposia! Dr. Watz, Medical Director and Principal Investigator at Velocity Clinical Research in Ahrensburg, Germany , joined Drs. Mona Bafadhel and Alberto Papi for a dynamic discussion, A Breath of Fresh Air: A Greater Understanding of COPD With Type 2 Inflammation.
Jupiter Neurosciences Makes Way in CNS Treatments with $11M IPO
XTalks
DECEMBER 4, 2024
Jupiter Neurosciences, a clinical-stage pharma company specializing in neuroinflammation, made its public market debut with an initial public offering (IPO) on the Nasdaq Capital Market under the symbol “JUNS.” The company priced 2,750,000 shares of common stock at $4.00 per share, expecting gross proceeds of $11 million. Trading began on December 3, 2024, with the IPO set to close the following day, subject to customary conditions.
How to Turn “Check-the-Box” Compliance Trainings Into Real Learning
Speaker: Brian Richardson, Brian Richardson, Founder and CEO of Richardson Consulting Group
Let’s face it—most ethics and compliance training programs aren’t winning awards for engagement. But that doesn’t mean they can’t be effective, captivating, and maybe even enjoyable! Join learning design expert Brian Richardson for a dynamic session on how to breathe new life into your ethics and compliance training. We'll explore innovative strategies to bring traditionally dry topics to life, making them resonate with learners and drive tangible change.
Clinical Trial Kitting: Avoid Costly Pitfalls
Imperical Blog
DECEMBER 4, 2024
Clinical trial kits, which contain necessary items for site visits like sample tubes, labels, and instructions, all conveniently customized by trial and visit, are a staple of clinical trials. On the surface, putting the kits together might seem simple enough, but it’s not. Read on… The post Clinical Trial Kitting: Avoid Costly Pitfalls appeared first on Imperial Clinical Research Services Blog.
December 4, 2024: In This Week’s PCT Grand Rounds, Large Language Models for Postmarketing Surveillance of Medical Products
Rethinking Clinical Trials
DECEMBER 4, 2024
Dr. Michael Matheny In this Friday’s PCT Grand Rounds, Michael Matheny of Vanderbilt University will present “Opportunities and Challenges in the Use of Large Language Models for Postmarketing Surveillance of Medical Products.” The Grand Rounds session will be held on Friday, December 6, 2024, at 1:00 pm eastern. Matheny is a professor of biomedical informatics, biostatistics, and medicine and the director of the Center for Improving the Public’s Health Through Informatic
Sign up to get articles personalized to your interests!
Clinical Research Informer brings together the best content for clinical researchers from the widest variety of industry thought leaders.
More Trending
10 Innovative Trends in Pharma Marketing: Strategies for Industry Success in 2025
Pharma Marketing Network
DECEMBER 4, 2024
Table of Contents Sr# Headings 1 Introduction 2 Digital Transformation in Pharma Marketing 3 Patient-Centric Marketing 4 Personalized Healthcare Campaigns 5 The Role of AI and Machine Learning 6 Leveraging Social Media Platforms 7 Data-Driven Decision Making 8 Omnichannel Marketing Strategies 9 The Power of Influencer Marketing 10 Navigating Regulatory Challenges 11 Sustainability in Pharma Marketing 12 Conclusion 13 FAQs Introduction Pharma marketing is undergoing a revolution.
Optimizing Generic Drug Development with Machine Learning
Drug Patent Watch
DECEMBER 4, 2024
The pharmaceutical industry is undergoing a significant transformation with the advent of machine learning methods. These methods have the potential to revolutionize the drug discovery process by enhancing the efficiency and accuracy of identifying and developing new drug candidates.
For first phase of Mounjaro's obesity rollout in England, only a limited number of patients will have access
Fierce Pharma
DECEMBER 4, 2024
Following its endorsement of Eli Lilly’s obesity medicine tirzepatide, England’s National Institute for Health and Care Excellence (NICE) has laid out plans for an unprecedented phased rollout that | Roughly 220,000 people in England will be eligible for the drug during the three-year launch phase. Afterward, officials plan to open access to a wider group of obesity patients, which numbers in the millions in England.
Lilly’s Zepbound beats Novo’s Wegovy in high-stakes obesity drug trial
Bio Pharma Dive
DECEMBER 4, 2024
Results from the head-to-head study showed treatment with Zepbound resulted in 47% greater relative weight loss than Wegovy, a finding that could advantage Lilly in the companies’ market competition.
Clinical Research White Paper – Enhancing Transparency & Efficiency Throughout the Trial Lifecycle
Advertisement
Enhancing Transparency & Efficiency Throughout the Trial Lifecycle for AI Readiness
Lilly’s Zepbound wins the weight loss duel with Novo’s Wegovy
Pharmaceutical Technology
DECEMBER 4, 2024
An open-label Phase III trial showed that participants using Zepbound saw 47% greater relative weight loss compared to Wegovy.
Antag, a startup backed by Versant and Novo, joins hunt for obesity drug alternatives
Bio Pharma Dive
DECEMBER 4, 2024
The company, which raised $84 million, sees validation of its GIP-blocking approach to weight loss in Amgen's recent MariTide drug data.
Maze Therapeutics raises $115m to advance kidney disease candidates
Pharmaceutical Technology
DECEMBER 4, 2024
Maze Therapeutics has completed a Series D financing round, raising $115m to propel the development of its lead candidates, MZE829 and MZE782.
Atea plans Phase 3 study for hepatitis C drug after mid-stage results
Bio Pharma Dive
DECEMBER 4, 2024
The struggling biotech company is looking to break into the lucrative hepatitis C market with the promise of an easier treatment regimen.
Can Your Organization Spot a Conflict Before It’s a Crisis?
Speaker: Amie Phillips Pablo, VP, Corporate Compliance & Privacy Officer at Novo Nordisk
In today’s complex healthcare environment, navigating third-party relationships has become even more challenging—whether it’s vendor relationships, employee activities, or patient-facing interactions. Left unmanaged, these conflicts can compromise trust, regulatory compliance, and even organizational reputation. So, how can healthcare teams stay ahead?
Ipsen and Biomunex enter agreement for cancer therapy
Pharmaceutical Technology
DECEMBER 4, 2024
Ipsen has entered an exclusive worldwide licensing agreement with Biomunex Pharmaceuticals to develop BMX-502.
Dewpoint, Mitsubishi partner on ALS drug in deal worth up to $480M
Bio Pharma Dive
DECEMBER 4, 2024
The collaboration is another vote of confidence in Dewpoint’s biomolecular condensates research, which had already attracted interest from the likes of Bayer and Novo Nordisk.
Takeda licensed for anaemia therapy by Keros Therapeutics
Pharmaceutical Technology
DECEMBER 4, 2024
Takeda has signed an agreement to receive an exclusive global licence from Keros Therapeutics for elritercept.
Antag Therapeutics secures €80 million in weight loss therapy financing
Pharma Times
DECEMBER 4, 2024
Versant Ventures leads investment round to advance drug
White Paper - A Roadmap to AI Data Readiness in R&D Labs
Advertisement
Download this comprehensive guide to AI and ML in the R&D Laboratory Setting.
UnitedHealthcare CEO Brian Thompson fatally shot in NYC
Bio Pharma Dive
DECEMBER 4, 2024
The NYPD confirmed the shooting, which caused UnitedHealth to end an investor conference early on Wednesday. Thompson, 50, had been with UnitedHealth since 2004.
Everest therapy shows promise in nephropathy trial
Pharma Times
DECEMBER 4, 2024
Data highlights effectiveness of EVER001 in treating pMN
Novavax sells Czech plant to Novo; Relay licenses out a cancer drug
Bio Pharma Dive
DECEMBER 4, 2024
Novo will pay $200 million to gain control of the protein manufacturing factory. Elsewhere, Roivant dropped a drug program and Takeda acquired a blood disease therapy.
Genmab expands its pipeline with $630m Scancell deal
pharmaphorum
DECEMBER 4, 2024
Genmab has licensed another anti-glycan antibody for cancer from UK biotech Scancell as it continues to expand its in-house pipeline.
Bridging Innovation & Patient Care: The Growing Role of AI
Speaker: Simran Kaur, Co-founder & CEO at Tattva.Health
AI is transforming clinical trials—accelerating drug discovery, optimizing patient recruitment, and improving data analysis. But its impact goes far beyond research. As AI-driven innovation reshapes the clinical trial process, it’s also influencing broader healthcare trends, from personalized medicine to patient outcomes. Join this new webinar featuring Simran Kaur for an insightful discussion on what all of this means for the future of healthcare!
FDA signs off on Merus' first-in-class NRG1+ cancer drug Bizengri after brief delay
Fierce Pharma
DECEMBER 4, 2024
Merus’ week keeps getting better. | The FDA had originally pushed its decision back by three months after a November manufacturing-related delay.
How automating flow cytometry is revolutionising cancer diagnosis and treatment
pharmaphorum
DECEMBER 4, 2024
Discover how the automation of flow cytometry is transforming cancer diagnosis and treatment for breast, prostate, endometrial, pancreatic, kidney, and melanoma cancers. Explore the latest advancements in the field.
With AstraZeneca exec under investigation in China, company names Reic new international chief
Fierce Pharma
DECEMBER 4, 2024
With AstraZeneca’s former international chief, Leon Wang, under investigation in China, the company has promoted an AZ veteran to fill the post. | With AstraZeneca’s former international chief, Leon Wang, under investigation in China, the company has promoted an AZ veteran to fill the post. The British giant has appointed Iskra Reic, Ph.D., as its new international executive vice president.
Brain-computer interfaces could redefine precision medicine
pharmaphorum
DECEMBER 4, 2024
Brain-computer interfaces, such as Elon Musk's Neuralink, have the potential to revolutionise precision medicine and transform how we understand and treat the brain. Learn more about this groundbreaking technology and its implications in healthcare.
From Diagnosis to Delivery: How AI is Revolutionizing the Patient Experience
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
Marketing Pharma: Proven Strategies to Stay Ahead in a Competitive Industry
Pharma Marketing Network
DECEMBER 4, 2024
Table of Contents Sr# Headings 1 Introduction 2 Understanding the Challenges in Marketing Pharma 3 Why Digital Transformation is Essential 4 Patient-Centric Marketing: Building Trust 5 Harnessing the Power of Omnichannel Marketing 6 Data-Driven Insights for Targeted Campaigns 7 Social Media in Pharma Marketing: Opportunities and Risks 8 AI and Automation: The Future of Marketing Pharma 9 Branded Content: Educate, Don’t Just Promote 10 Navigating Regulatory Hurdles 11 Sustainability: A Growing De
Warning letter adds to Applied Tx run of bad news
pharmaphorum
DECEMBER 4, 2024
Applied Therapeutics gets a warning letter from the FDA over a trial of rare disease drug govorestat, which was rejected by the agency last week
Drug Patent Expirations for the Week of December 1, 2024
Drug Patent Watch
DECEMBER 4, 2024
SUMAVEL DOSEPRO (sumatriptan succinate) Endo operations Patent: 8,287,489 Expiration: Dec 6, 2024 See More … Source
Driving innovation in multiple myeloma to improve the patient experience
pharmaphorum
DECEMBER 4, 2024
Discover how driving innovation in multiple myeloma treatment can positively impact the patient experience. Stay informed on the latest advancements in cancer research and patient care.
Let's personalize your content